Astrazeneca (AZN) Interest & Investment Income (2009 - 2026)

Astrazeneca has reported Interest & Investment Income for 18 years, with the latest figure at $80.0 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 17.65% year-over-year to $80.0 million in Q2 2026; TTM through Jun 2026 was $373.0 million, a 6.52% decrease from a year earlier, with the FY2025 full-year figure at $360.0 million, down 21.4% from the prior year.
• Interest & Investment Income was $80.0 million for Q2 2026 at Astrazeneca, up from $73.0 million in the prior quarter.
• The five-year high for Interest & Investment Income was $183.0 million in Q3 2024, with the low at $15.0 million in Q3 2022.
• Average Interest & Investment Income over 5 years is $79.4 million, with a median of $79.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income surged 4400.0% in 2022, then tumbled 53.55% in 2025.
• Over 5 years, Interest & Investment Income stood at $45.0 million in 2022, then soared by 140.0% to $108.0 million in 2023, then plunged by 40.74% to $64.0 million in 2024, then surged by 110.94% to $135.0 million in 2025, then plunged by 40.74% to $80.0 million in 2026.
• The last three Interest & Investment Income figures came in at $80.0 million (Q2 2026), $73.0 million (Q1 2026), and $135.0 million (Q4 2025), per Business Quant data.